Related Experiment Video
Updated: Jul 5, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Asthma-related medication use among children in the United States
James J Korelitz1, Julie M Zito, Norma I Gavin
1Westat, Rockville, Maryland 20850, USA. JamesKorelitz@Westat.com
Insights
Asthma medications are dispensed to 15% of children, including many without an asthma diagnosis. More pediatric drug safety and pharmacokinetic data are needed.
Area of Science:
- Pediatric pharmacology
- Public health
- Health services research
Background:
- Asthma significantly impacts children's health and healthcare utilization.
- The Best Pharmaceuticals for Children Act necessitates pediatric drug evaluations.
- Understanding pediatric asthma medication use is crucial for drug prioritization.
Purpose of the Study:
- To determine the percentage of children receiving asthma-related medications.
- To assess medication dispensing patterns in relation to asthma diagnoses in children.
Main Methods:
- Retrospective analysis of U.S. outpatient medical and drug claims (2004-2005).
- Study included over 4.2 million children aged 0-17 years.
- Examined medication dispensing for children with and without asthma diagnoses.
Main Results:
- 15% of all children received an asthma-related medication.
- 86% of children with an asthma diagnosis received medication.
- 10% of children without an asthma diagnosis also received asthma medication.
Conclusions:
- A substantial proportion of children receive asthma medications, including those without a formal asthma diagnosis.
- Significant knowledge gaps exist regarding the safety and pharmacokinetics of these medications in pediatric populations.
- Further clinical studies utilizing novel approaches are required to address these data deficiencies.
Background:
Asthma is one of the most common chronic conditions in children and has a major impact on health care use and quality of life. The Best Pharmaceuticals for Children Act mandates the federal government to sponsor pediatric studies of drugs approved for use in the United States but lacking evaluation in the pediatric population and lacking interest of commercial sponsors. As input into the drug selection and prioritization process, information is needed on the percentage of children who receive asthma-related medications.
Objective:
To estimate the percentage of children who receive asthma-related medications.
Methods:
Retrospective analysis of outpatient medical and drug claims from members of commercial health care insurance plans enrolled any time from January 1, 2004, through December 31, 2005. The study population included 4,259,103 children throughout the United States aged birth through 17 years.
Results:
Fifteen percent of all children were dispensed an asthma-related medication. Among 218,943 children with an asthma diagnosis, 188,286 (86%) had a dispensed asthma-related medication at any time during the 2-year study period. Among children without any asthma diagnoses, 398,880 (10%) had a dispensed medication. Fifty-nine percent of children with an asthma diagnosis were dispensed an anti-inflammatory medication within 90 days after a claim with a diagnosis of asthma.
Conclusions:
Asthma-related medications are dispensed to a large percentage of the pediatric population, including many who do not have claims with asthma diagnoses listed. Data on the pharmacokinetics and safety of these drugs in children are largely unknown and difficult to obtain. Clinical studies that use new tools and approaches are needed to resolve this information gap.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Asthma-I: Introduction
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...